# A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Alendronic Acid on Alveolar Bone Remodeling After Tooth Extraction

> **NCT05602493** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Xeolas Pharmaceuticals Limited** · enrollment: 60 (actual)

## Conditions studied

- Bone Loss, Alveolar

## Interventions

- **DRUG:** Soludronate®
- **DRUG:** sterile saline

## Key facts

- **NCT ID:** NCT05602493
- **Lead sponsor:** Xeolas Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-22
- **Primary completion:** 2024-10-20
- **Final completion:** 2024-10-20
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05602493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05602493, "A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Alendronic Acid on Alveolar Bone Remodeling After Tooth Extraction". Retrieved via AI Analytics 2026-09-11 from https://api.ai-analytics.org/clinical/NCT05602493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*